User profiles for "author:J E Gray"

Julie E Gray

University of Sheffield
Verified email at sheffield.ac.uk
Cited by 13233

Protective coatings on magnesium and its alloys—a critical review

JE Gray, B Luan - Journal of alloys and compounds, 2002 - Elsevier
Magnesium and its alloys have excellent physical and mechanical properties for a number
of applications. In particular its high strength: weight ratio makes it an ideal metal for …

Influence of environmental factors on stomatal development

S Casson, JE Gray - New phytologist, 2008 - Wiley Online Library
Stomata play a pivotal role in the regulation of gas exchange in flowering plants and are
distributed throughout the aerial epidermis. In leaves, the pattern of stomatal distribution is …

[HTML][HTML] Impact of stomatal density and morphology on water-use efficiency in a changing world

LT Bertolino, RS Caine, JE Gray - Frontiers in plant science, 2019 - frontiersin.org
Global warming and associated precipitation changes will negatively impact on many
agricultural ecosystems. Major food production areas are expected to experience reduced …

[HTML][HTML] Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

L Gandhi, D Rodríguez-Abreu, S Gadgeel… - New England journal …, 2018 - Mass Medical Soc
Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

[HTML][HTML] Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

JC Soria, Y Ohe, J Vansteenkiste… - New England journal …, 2018 - Mass Medical Soc
Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …

[HTML][HTML] Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

SJ Antonia, A Villegas, D Daniel… - … England Journal of …, 2017 - Mass Medical Soc
Background Most patients with locally advanced, unresectable, non–small-cell lung cancer
(NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy …

[HTML][HTML] Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC

SJ Antonia, A Villegas, D Daniel… - … England Journal of …, 2018 - Mass Medical Soc
Background An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage …

[HTML][HTML] Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

DR Spigel, C Faivre-Finn, JE Gray… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with
unresectable, stage III non–small-cell lung cancer and no disease progression after …

[HTML][HTML] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

SS Ramalingam, J Vansteenkiste… - … England Journal of …, 2020 - Mass Medical Soc
Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …

Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell …

S Gadgeel, D Rodríguez-Abreu, G Speranza… - Journal of clinical …, 2020 - ascopubs.org
PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum
significantly improved overall survival (OS) and progression-free survival (PFS) compared …